Can Obama Help Vete...
Health Care: Drugs
AstraZeneca PLC (AZN: NYSE)
$40.08 -0.33 | -0.82%
06/01/12 - 04:01 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 0.00 | 10.98B | 0.00 | 8.68B |
| Operating Gains/Losses | 428.00M | 0.00 | 0.00 | -2.44B |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -1.11B | 10.00M | -256.00M | -1.03B |
| (Increase) Decrease in Inventories | -256.00M | 88.00M | 6.00M | 185.00M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 467.00M | -16.00M | 1.58B | 637.00M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | 0.00 | 0.00 | -200.00M | 0.00 |
| Other Non-Cash Items | 5.74B | -3.12B | 8.52B | 87.00M |
| Net Cash From Continuing Operations | 7.82B | 10.68B | 11.74B | 8.74B |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 7.82B | 10.68B | 11.74B | 8.74B |
| Sale of Property, Plant & Equipment | 102.00M | 293.00M | 407.00M | 38.00M |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 1.00M |
| Purchases of Property, Plant & Equipment | -1.30B | -2.18B | -2.96B | -4.04B |
| Acquisitions | 1.77B | -348.00M | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | -239.00M | 0.00 | 0.00 |
| Other Cash from Investing Activities | -2.59B | 164.00M | 102.00M | 112.00M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -2.02B | -2.34B | -2.48B | -3.90B |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 787.00M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 409.00M | 494.00M | 135.00M | 159.00M |
| Repayment of Long-Term Debt | 46.00M | -1.75B | -787.00M | -3.96B |
| Repurchase of Capital Stock | -6.02B | -2.60B | 0.00 | -610.00M |
| Payment of Cash Dividends | -3.76B | -3.36B | -2.98B | -2.74B |
| Other Financing Charges, Net | 3.00M | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | -9.32B | -7.22B | -3.63B | -6.36B |
| Effect of Exchange Rate Changes | -25.00M | 33.00M | 71.00M | -88.00M |
| Net Change in Cash & Cash Equivalents | -3.55B | 1.15B | 5.70B | -1.60B |
Portfolios with AZN
- Portfolio NameUser Type
- UserGFNN Stockdiagnostics 14
- UserThe Coming M&A boom
- ContributorHighest-Yielding Drug Stocks
- Contributor10 Dividend Stocks Still Pa...
- User2012 performers
- Contributor6 European Stocks Resistant...
- UserMoney Maker
- Userkeithj
- ContributorRocket Stocks for the Week ...
- ProJohn Hussman
Latest AZN Headlines from TheStreet
- 9 High-Yield Stocks to Consider in Lieu of Bonds 06.01.12 | 01:06 pm
- AstraZeneca PLC (AZN): Today's Featured Health Care Winner 05.03.12 | 05:05 pm
- The Next Big Thing in Biotech: M&A
04.27.12 | 05:04 am - AstraZeneca PLC (AZN): Today's Featured Drugs Loser 04.26.12 | 05:04 pm
- Rupert Murdoch in Second Day of Testimony: Hot Trends 04.26.12 | 08:04 am
- 14 Deal-Ready Stocks for the M&A Boom 04.26.12 | 06:04 am
- AstraZeneca Buys Ardea Biosciences for $1.26 Billion: Hot Trends 04.23.12 | 10:04 am
- AstraZeneca Buys Ardea Biosciences for $1.26B: Hot Trends 04.23.12 | 08:04 am
- AstraZeneca Wins Patent Protection on Seroquel: Hot Trends 03.30.12 | 10:03 am
- Stocks to Watch: Research In Motion, Dunkin' Brands (Update 1) 03.30.12 | 08:03 am
Press Releases for AZN
- Data Presented At The European Atherosclerosis Society Congress Reinforces The Differentiating Benefits Of CRESTOR[TM] In Comparison To Atorvastatin And Simvastatin - PR Newswire 05.28.12 | 01:05 am
- SYMBICORT® (budesonide/formoterol Fumarate Dihydrate) Long-Term Study Shows Similar Safety Profile When Compared To Budesonide Monotherapy In African-American Patients With Asthma - Business Wire 05.10.12 | 09:05 am
- LUNAR Examines Cholesterol-Lowering Effects Of CRESTOR® (rosuvastatin Calcium) Compared With Atorvastatin In Patients With Acute Coronary Syndrome - Business Wire 05.01.12 | 09:05 am
- AstraZeneca And The Medicines Company Announce Global Collaboration In Acute Ischemic Heart Disease - Business Wire 04.25.12 | 12:04 pm
- AstraZeneca Launches DUTOPROL™ (metoprolol Succinate Extended Release/hydrochlorothiazide) Tablets For High Blood Pressure In U.S. - Business Wire 04.12.12 | 09:04 am
- US District Court Finds SEROQUEL XR Formulation Patent Valid And Infringed - Business Wire 03.29.12 | 05:03 pm
- Crestor Delivers Latest LDL-C Targets In High-Risk Patients At Lower Doses Than Other Statins - PR Newswire 03.26.12 | 01:03 pm
- US Court Denies Preliminary Injunction Application Against The FDA And Dismisses AstraZeneca’s Lawsuit Without Prejudice - Business Wire 03.26.12 | 02:03 am
- New Data Suggests Results Of PLATO Genetic Sub-Study Outcomes For BRILINTA® (Ticagrelor) Not Driven By Poor Metabolizers Of Clopidogrel - Business Wire 03.25.12 | 11:03 am
- New Data Suggests BRILINTA® (ticagrelor) Reduced First And Recurrent Cardiovascular And Ischemic Events - Business Wire 03.25.12 | 11:03 am
Partner Headlines for AZN
- Healthcare Biz Recap: Aeterna Zentaris Shares Surge, J&J Files with FDA - Wall St. Cheat Sheet 05.31.12 | 10:05 am
- Analyst Insights: Finish Line, BioMarin Pharma, Laboratory Corp, Ocz Technology, AstraZeneca May 31st - Wall St. Cheat Sheet 05.31.12 | 10:05 am
- 6 FTSE100 6%+ Dividend Yielders - Seeking Alpha 05.20.12 | 08:05 am
- Merger Arbitrage Mondays - May 14, 2012 - Seeking Alpha 05.14.12 | 09:05 am
- 4 New Reasons To Be Bullish On Sanofi Now - Seeking Alpha 05.13.12 | 09:05 am
- This Developmental Pharma Has Potential To Be A Long Term Multibagger - Seeking Alpha 05.03.12 | 09:05 am
- Spectrum: Increased Fusilev Production May Boost Stock - Seeking Alpha 04.30.12 | 09:04 am
- Benzinga's M&A Chatter for Friday April 27, 2012 - Benzinga 04.28.12 | 08:04 pm
- Earnings Recap for April 26, 2012 - Benzinga 04.26.12 | 09:04 am
- Amgen Beats but Maintains Outlook - Analyst Blog - Zacks 04.25.12 | 10:04 am
